Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

DEVON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2018 and provided an overview of recent operational highlights.

“The momentum we established in the first half of 2018 continued through the third quarter,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We began enrolling patients into CONNECT-FX, our pivotal study in Fragile X syndrome and we expect to complete enrollment in BELIEVE-1, our Phase 2 study in developmental and epileptic encephalopathies, before year end. With our third quarter 2018 follow-on offering, we are well capitalized and expect our current cash to take us through the presentation of top line data for both of these studies.”

Third Quarter 2018 and Recent Highlights

ZYN002 in Fragile

... read more at: https://globenewswire.com/news-release/2018/11/08/1647773/0/en/Zynerba-Pharmaceuticals-Reports-Third-Quarter-2018-Financial-Results-and-Operational-Highlights.html


All brands and product names are trademarked or registered trademarks of their respective companies.
Copyright of syndicated content belongs to it’s respective author or news organization.
Original content is Copyright © 2016 - CBD Case Studies - All Rights Reserved.
Email: - Bhang Domains: Cannabis Domain Names.
Hosted at JD Domains. Powered by WordPress and Rakiya.